


Disclosures · I have no disclosures. Montefiore EINSTEIN

2


4



What are eConsults? Brief summary of the patient's relevant history, exam, and findings Questions for the e-consultant. Assessment Recommendations
Comment on need for specialist appointment Montefiore EINSTEIN

## Effectiveness of eConsults Provider-to-provider asynchronous messaging Improved access to specialties, high levels of patient and provider satisfaction, lower medical costs Avoidance of face-to-face specialist appointments in 12-84% Nephrology: traditional consult avoided in 45% - Endocrinology: traditional consults avoided in 44-67% Liddy C, et al. Family Practice 2016. Keely E, et al. Can J Kidney Health Dis 2018. Tran CS, et al. Endocr Pract 2016 Montefiore EINSTEIN





Hypotheses

- · We hypothesized that:
  - 1. There would be high demand
  - 2. Specific questions re: choice of opioid, opioid tapering, UDT interpretation, etc.
  - 3. A minority would lead to specialist visits

Montefiore EINSTEIN

7

9

8

## Study methods and analysis

- eConsults ordered July 1, 2019-Feb 28, 2020
   Data collection: Demographics, textual data about
  - questions and responses
- Mixed methods
  - Utilization:
  - Frequency of eConsults


  - Provider and patient characteristics
     Types of questions and recommendations
    - Qualitative analysis of provider questions and specialist recommendations
  - Specialist appointments
    - Proportion of eConsults in which face-to-face specialist appointment were recommended and completed



Montefiore EINSTEIN

Results: utilization

- 25 eConsults requested in first 8 months, from 17 providers
- All responded to within 72 hours



10

54 years (53.68, 31-86) 17 (68)
17 (68)
17 (00)
15 (60)
21 (84)
10 (40) 8 (20) 2 (8) 2 (8)

Types of providers' questions to eConsultants

- - "Please suggest a regimen that may be more effective in controlling her pain."
  - "Please recommend alternative regimens and non-opioid analgesics... - ".....Tapering of chronic opioids"
- Specific
  - "Could you please assist in suggesting longer acting formulations?"


  - "Can fentanyl or hydrocodone show up as oxycodone in urine tox screen?"

     "Can you recommend transdermal buprenorphine induction strategies for this patient, if you agree that this would be an option for the patient?"
  - "Is there another opioid of similar potency to norco 7.5 325 mg that the patient could take instead?"


Montefiore EINSTEIN


11 12

Provider Questions to eConsultant (n=25) Montefiore EINSTEIN




13 14







Types of eConsultant recommendations Non-opioid pharmacological medications Non-pharmacological measures e.g. physical therapy, mental health assessment Judicious opioid prescribing Weighing risk-benefit ratio to continue or reduce dose Monitoring through use of controlled substance agreement, UDT Harm reduction (naloxone prescribing)
 Interoretation of urine drug testing including education around screening vs. confirmation <u>Guidance around use of specific medications</u> e.g. buprenorphine, long-acting formulations of opioids Montefiore EINSTEIN





17 18






19 20





21 2





23 24

## Acknowledgements

- Sharon Rikin, MD MS
  Joanna Starrels, MD MS
  Tiffany Lu, MD MS
  Daniel Lipsey
  Yaron Tomer, MD
  Julia Arnsten, MD MPH
  Aloke Maity
  Montefiore IT team
  CMS Delivery System Reform Incentive Payments (DSRIP) Innovation Fund



